Thailand Cannabis Reversal: From Decriminalization to Re-Criminalization

Executive Summary

Thailand's historic 2022 cannabis decriminalization—which briefly made it the first Asian nation to legalize recreational use—has been reversed through legislation that recriminalized recreational cannabis in 2025, leaving thousands of dispensaries in legal limbo and billions of baht in investments stranded. The reversal followed intense political pressure from conservative factions, public health concerns over youth access, and a chaotic regulatory vacuum that saw cannabis shops proliferate from fewer than 100 to over 6,000 in just 18 months. The new law, which took effect January 1, 2026, restricts cannabis to medical use only under strict prescription requirements, effectively dismantling Southeast Asia's most liberal cannabis experiment and sending shockwaves through regional markets from Malaysia to Singapore that had been watching Thailand's model closely. The policy whiplash has created a humanitarian and economic crisis: an estimated 4,800 dispensaries have closed permanently, over 30,000 jobs have been eliminated, and patient access to medical cannabis has become severely restricted despite the government's stated intent to preserve therapeutic pathways. Foreign investors, particularly from Canada and the United States, have written off an estimated $2.3 billion in capital deployed between 2022 and 2024. The reversal represents one of the most dramatic cannabis policy failures in modern history and serves as a cautionary tale for emerging markets considering liberalization without comprehensive regulatory frameworks.

Why This Matters

Thailand's cannabis reversal affects an estimated 1.2 million registered medical cannabis patients, 125,000 farmers who cultivated legal cannabis between 2022-2025, and sets a precedent that could delay liberalization efforts across Asia for a decade or more. The stakeholder impact extends across multiple dimensions. For patients, particularly those managing chronic pain, epilepsy, and chemotherapy side effects, the recriminalization has created immediate access barriers. Under the new law, patients must obtain prescriptions from one of only 89 government-approved physicians nationwide—down from over 2,000 practitioners who could recommend cannabis under the 2022-2024 framework. Wait times for appointments now average 6-8 weeks according to the Thai Ministry of Public Health, forcing many patients back to opioid-based treatments or underground markets. Economically, the reversal has destroyed an estimated 89 billion baht ($2.6 billion USD) in market value. The Thai Cannabis Corporation, a publicly-traded aggregator of dispensary chains, saw its stock price collapse 94% between November 2025 and March 2026. International cannabis companies including Canopy Growth, Tilray, and Aurora Cannabis had collectively invested over $800 million in Thai cultivation facilities, processing infrastructure, and retail partnerships—investments now classified as total losses in their 2026 annual reports. The agricultural impact has been particularly severe in northern provinces. In Chiang Mai, Chiang Rai, and Mae Hong Son, an estimated 45,000 smallholder farmers transitioned from opium poppy cultivation to legal cannabis between 2022-2024 as part of government-encouraged crop substitution programs. These farmers, many from ethnic minority hill tribes, invested family savings and took loans to build greenhouses and drying facilities. The reversal has left them with unsellable inventory—approximately 180 metric tons of dried flower as of June 2026—and no legal market to absorb it. The Thai Farmers Association reported a 340% increase in farmer suicides in northern provinces between January-May 2026 compared to the same period in 2025, though the government disputes the methodology of these figures. Geopolitically, Thailand's reversal has emboldened prohibitionist factions across Southeast Asia. Malaysia's Health Ministry cited Thailand's "failed experiment" when rejecting a 2026 medical cannabis proposal. Singapore's Ministry of Home Affairs referenced Thai youth usage statistics in parliamentary testimony defending its mandatory death penalty for cannabis trafficking. The reversal has effectively frozen regional liberalization momentum that had been building since 2020.

Background and History: From Decriminalization to Reversal

Thailand's cannabis journey from traditional medicine to prohibition to brief legalization and back to criminalization spans over a century and reflects deeper tensions between modernization, Western influence, and cultural identity.

Traditional Use and Colonial-Era Prohibition (1800s-1930s)

Cannabis has been used in traditional Thai medicine for centuries, documented in the Ayurvedic-influenced Tamra Phaet Thai medical texts dating to the Ayutthaya period (1351-1767). Thai traditional medicine practitioners used cannabis leaves and flowers to treat pain, digestive disorders, and as an appetite stimulant. The plant grew wild throughout the kingdom and was cultivated in household gardens alongside other medicinal herbs. Thailand's prohibition began under international pressure. The country became a signatory to the 1925 International Opium Convention, which classified cannabis as a dangerous narcotic despite limited domestic concern about its use. In 1934, Thailand passed the Cannabis Act under Prime Minister Plaek Phibunsongkhram's government, which was pursuing modernization policies aligned with Western medical models. The law made cultivation, possession, and sale illegal, though enforcement remained minimal in rural areas where traditional use continued.

Strict Enforcement Era and the War on Drugs (1960s-2010s)

Cannabis enforcement intensified dramatically in the 1960s and 1970s as Thailand became a major transit route for heroin from the Golden Triangle. The government, under pressure from the United States during the Vietnam War era, implemented harsh penalties. The 1979 Narcotics Act classified cannabis as a Category 5 narcotic, carrying penalties of up to 15 years imprisonment for possession and life imprisonment or death for trafficking quantities over 10 kilograms. Thailand's drug war reached its peak lethality during Prime Minister Thaksin Shinawatra's 2003 "War on Drugs" campaign, which resulted in approximately 2,800 extrajudicial killings according to Human Rights Watch. While primarily targeting methamphetamine, the campaign reinforced cannabis prohibition and created a climate of fear around all drug policy reform discussions. Despite strict laws, cannabis use persisted. A 2017 survey by Mahidol University estimated that 1.2% of Thai adults (approximately 620,000 people) had used cannabis in the previous year, with higher rates among youth in tourist areas and urban centers.

Medical Legalization and the Path to Decriminalization (2018-2022)

The reform movement began with medical legalization. In December 2018, Thailand's National Legislative Assembly voted 166-0 to amend the Narcotics Act to allow medical cannabis use, making Thailand the first Southeast Asian nation to take this step. The law, which took effect in February 2019, permitted licensed medical facilities to prescribe cannabis for specific conditions including chemotherapy side effects, epilepsy, and chronic pain. The medical program initially operated under highly restrictive conditions. Only government hospitals and approved traditional medicine clinics could dispense cannabis products. The Government Pharmaceutical Organization held a monopoly on cultivation and processing. Patient access remained limited, with only approximately 4,200 patients receiving cannabis treatments in 2019 according to the Thai Food and Drug Administration. The breakthrough came under the government of Prime Minister Prayut Chan-o-cha. Anutin Charnvirakul, leader of the Bhumjaithai Party and Deputy Prime Minister, made cannabis liberalization a signature policy platform. Bhumjaithai had campaigned on cannabis reform in the 2019 elections, positioning it as an economic development opportunity for rural farmers and a way to reclaim traditional Thai medicine from Western pharmaceutical dominance. On June 9, 2022, Thailand removed cannabis and hemp from its Category 5 narcotics list, effectively decriminalizing the plant. The move was implemented through ministerial regulation rather than comprehensive legislation—a decision that would later prove catastrophic. The decriminalization allowed individuals to grow cannabis at home after registering with the government, and permitted commercial cultivation and sale for "medical and health" purposes.

The Cannabis Boom (2022-2024)

The regulatory vacuum created an unprecedented commercial explosion. Within three months of decriminalization, over 1,200 cannabis dispensaries opened across Thailand, concentrated in Bangkok, Phuket, Chiang Mai, and Pattaya. By December 2023, the number had reached 6,127 registered dispensaries according to the Thai FDA, with an estimated 2,000-3,000 additional unlicensed operations. The dispensaries operated in a legal gray zone. While the June 2022 ministerial order decriminalized cannabis, it did not create a comprehensive regulatory framework for recreational sales. Dispensaries marketed products as "medical" or "wellness" items, but in practice operated as de facto recreational retailers. Products ranged from traditional dried flower to edibles, vapes, and cannabis-infused beverages. Prices dropped precipitously: high-grade flower that sold for 800-1,000 baht per gram on the black market in 2021 fell to 150-300 baht per gram by mid-2023. Foreign investment poured in. Canadian licensed producers including Supreme Cannabis and WeedMD announced Thai joint ventures. U.S.-based multistate operators explored franchise models. Israeli agricultural technology companies partnered with Thai cultivators to build climate-controlled greenhouses. The Thai Cannabis Corporation, founded in 2022, raised $340 million through a Bangkok Stock Exchange IPO in March 2023 at a valuation of $1.8 billion. Tourism marketing embraced cannabis. The Tourism Authority of Thailand soft-launched "cannabis tourism" campaigns targeting international visitors, particularly from markets where cannabis remained illegal. Hotels in Phuket and Koh Samui added "cannabis wellness" packages. Cooking schools offered cannabis-infused Thai cuisine classes. International arrivals to Thailand increased 23% in 2023 compared to 2019 pre-pandemic levels, with tourism officials privately attributing 8-12% of the increase to cannabis liberalization, though no official study confirmed this correlation.

The Backlash Builds (2023-2024)

Opposition coalesced around several concerns. Public health officials raised alarms about youth access. A September 2023 survey by the Department of Mental Health found that 8.7% of Thai secondary school students reported trying cannabis since decriminalization, up from 1.3% in a 2021 survey. Emergency room visits for cannabis-related issues increased 340% between June 2022 and June 2023 according to data from 43 public hospitals compiled by the Ministry of Public Health. Conservative Buddhist organizations mobilized against liberalization. The Sangha Supreme Council, Thailand's governing body for Theravada Buddhism, issued a statement in November 2023 declaring cannabis use contrary to the Fifth Precept against intoxication. Prominent monks including Phra Buddha Isara organized rallies calling for recriminalization, framing cannabis as a Western import corrupting Thai youth and traditional values. The political landscape shifted. In the May 2023 elections, the progressive Move Forward Party won the most seats with a platform including full cannabis legalization, but was blocked from forming a government by conservative senators. The eventual coalition government, led by Prime Minister Srettha Thavisin of the Pheu Thai Party, included parties opposed to liberalization. Bhumjaithai Party, the original champion of decriminalization, saw its parliamentary seats decline from 51 to 71, but lost leverage in coalition negotiations. The military and police establishment opposed liberalization. Senior generals viewed the cannabis boom as undermining drug enforcement credibility and creating opportunities for organized crime infiltration. The Royal Thai Police reported that methamphetamine seizures had increased 67% in 2023 compared to 2022, which officials attributed to traffickers using legal cannabis businesses as fronts—though independent analysts questioned this causal link.

The Recriminalization Push (2024-2025)

In March 2024, the Thai Parliament began debating the Cannabis Control Act, legislation that would restrict cannabis to medical use only. The bill passed its first reading 248-142 in May 2024, with support from Pheu Thai, the Democrat Party, and military-aligned senators. Bhumjaithai Party led opposition but lacked votes to block passage. The legislation stalled through mid-2024 as the government negotiated transition provisions. Dispensary owners and farmers organized protests. A June 2024 rally in Bangkok drew an estimated 15,000 participants. The Thai Cannabis Trade Association filed constitutional challenges arguing the recriminalization violated property rights and legitimate expectations created by the 2022 decriminalization. The Constitutional Court rejected the challenges in September 2024, ruling that the 2022 decriminalization had been implemented through ministerial regulation rather than statute, and therefore created no protected rights. The decision cleared the path for recriminalization. The Cannabis Control Act passed its final reading on November 8, 2024, by a vote of 256-144. King Maha Vajiralongkorn signed the law on November 30, 2024, with an effective date of January 1, 2026—giving businesses and patients a 13-month transition period.

Implementation and Aftermath (2026-Present)

The transition period saw a desperate selloff. Dispensaries liquidated inventory at steep discounts. Cultivators harvested crops early to sell before the deadline. Cross-border smuggling to Malaysia, Laos, and Cambodia increased sharply, with Thai police seizing over 12 metric tons of cannabis at border crossings between November 2024 and December 2025. On January 1, 2026, the Cannabis Control Act took effect. The law restricts cannabis to medical use under prescription from licensed physicians. Recreational possession of any amount became a criminal offense punishable by up to one year imprisonment and fines up to 20,000 baht. Cultivation without a medical license carries penalties of 5-15 years imprisonment. The medical framework proved highly restrictive. Only 89 physicians nationwide completed the required certification program by January 2026. Approved conditions are limited to chemotherapy side effects, epilepsy refractory to other treatments, chronic pain in terminal illness, and multiple sclerosis. Patients must obtain prescriptions from certified physicians and fill them at one of 127 government-approved pharmacies. As of June 2026, only 14,200 patients have successfully obtained legal medical cannabis under the new system—down from an estimated 1.2 million who accessed cannabis through dispensaries during the 2022-2025 period. The Ministry of Public Health attributes the low numbers to the system still "ramping up," while patient advocates describe a system designed to minimize access.

Key Players

Anutin Charnvirakul and Bhumjaithai Party

Anutin Charnvirakul, leader of the Bhumjaithai Party and former Deputy Prime Minister, championed Thailand's 2022 decriminalization but lost political capital when the policy generated backlash. Anutin framed cannabis reform as economic nationalism—a way for Thai farmers to compete globally and reclaim traditional medicine from Western pharmaceutical companies. His party's electoral success in 2019 was partly attributed to cannabis policy appeals to rural voters. Following the reversal, Anutin has maintained that decriminalization was correct but implemented too quickly without adequate regulatory preparation. Bhumjaithai lost significant support in Bangkok and urban areas in the 2023 elections, though it retained its rural base in northeastern Thailand.

Thai Ministry of Public Health

The Ministry of Public Health emerged as the primary institutional opponent of broad liberalization. Minister Cholnan Srikaew, a physician by training, testified repeatedly before Parliament about youth usage concerns and emergency room data. The Ministry's Department of Mental Health released studies showing increased cannabis-related psychiatric admissions, though methodology was disputed by reform advocates. Following recriminalization, the Ministry controls the medical cannabis program through licensing of physicians and pharmacies. Critics argue the Ministry has deliberately created bottlenecks to minimize access, while officials maintain they are prioritizing patient safety and evidence-based medicine.

Thai Food and Drug Administration (FDA)

The Thai FDA administered the dispensary registration system during the 2022-2025 period and now oversees medical cannabis product approvals. The agency registered 6,127 dispensaries and over 125,000 individual cultivators during liberalization. The FDA faced criticism from both sides—reformers argued it failed to enforce quality standards or prevent sales to minors, while conservatives blamed it for enabling the cannabis boom through lax oversight. Under the new regime, the FDA has approved only 23 cannabis products for medical use, all produced by the Government Pharmaceutical Organization or licensed domestic manufacturers. No imported products have been approved.

Government Pharmaceutical Organization (GPO)

The GPO, a state enterprise under the Ministry of Public Health, holds a near-monopoly on legal medical cannabis production. The organization operates cultivation facilities in Khon Kaen and Nakhon Phanom provinces with approximately 45 hectares under production. The GPO produces cannabis oils, capsules, and sublingual sprays sold through government pharmacies. Pricing is significantly higher than black market alternatives—a 10ml bottle of 5% THC oil costs 3,500 baht through the GPO compared to 800-1,200 baht for equivalent products from underground sources. The GPO reported revenues of 89 million baht from cannabis products in the first quarter of 2026, well below projections of 400-600 million baht annually.

Thai Cannabis Trade Association

This industry group, formed in July 2022, represented dispensary owners and cultivators during the boom period. The association lobbied against recriminalization and organized legal challenges and protests. Following the reversal, the organization has pivoted to advocating for compensation for businesses and farmers who made investments in reliance on the 2022 decriminalization. The association claims its members collectively lost over 67 billion baht in inventory, equipment, and lease obligations. The government has offered no compensation program, arguing that businesses operated in a known legal gray area and assumed regulatory risk.

International Investors

Foreign cannabis companies entered Thailand aggressively during 2022-2024. Canopy Growth Corporation announced a $180 million joint venture with Thai partner Siam Wellness Group in August 2022 to build cultivation and processing facilities. Tilray Brands invested $95 million in a Bangkok-based distribution company. Aurora Cannabis partnered with Thai agricultural conglomerate Charoen Pokphand Group on greenhouse development. All three companies wrote off their Thai investments as total losses in 2025-2026 financial statements. The experience has made international cannabis companies highly cautious about emerging market investments, with several executives citing Thailand in earnings calls as a lesson in political risk assessment.

Patient Advocacy Groups

Organizations including the Thai Cannabis Patient Network and Medical Marijuana Thailand Foundation have documented access barriers under the new system. These groups maintain that the restrictive medical framework violates patient rights and forces people back to dangerous pharmaceutical alternatives or underground markets. They have filed petitions with the National Human Rights Commission and organized small-scale protests, but lack the political influence to reverse the policy. Patient advocates estimate that fewer than 2% of legitimate medical cannabis patients have maintained legal access under the 2026 system.

Legal and Regulatory Framework

Thailand's cannabis legal framework shifted from the 1979 Narcotics Act prohibition to the 2022 ministerial decriminalization to the 2024 Cannabis Control Act recriminalization—a regulatory whiplash that created legal chaos and destroyed investor confidence. The foundational law remains the Narcotics Act, B.E. 2522 (1979), which classified cannabis as a Category 5 narcotic alongside heroin and methamphetamine. The 2018 amendment to this Act created an exception for medical use under licensed conditions, but maintained criminal penalties for recreational possession and trafficking. The June 9, 2022 decriminalization occurred through a ministerial notification issued under Section 22 of the Narcotics Act, which allows the Minister of Public Health to remove substances from the controlled substances list. This notification removed cannabis and hemp from Category 5, effectively decriminalizing possession and cultivation. However, the notification did not create a comprehensive regulatory framework for commercial sales, taxation, quality control, or age restrictions—gaps that proved fatal to the policy. The Cannabis Control Act, B.E. 2567 (2024), which took effect January 1, 2026, re-established cannabis prohibition with a medical exception. Key provisions include: Section 7 restricts cannabis use to medical purposes under prescription from a licensed physician. Approved conditions are limited to those specified in Ministry of Public Health regulations. Section 12 prohibits recreational possession of any amount of cannabis, with penalties of up to one year imprisonment and fines up to 20,000 baht for first offenses. Repeat offenses carry penalties of 1-5 years imprisonment. Section 15 prohibits cultivation without a medical production license issued by the Thai FDA. Unlicensed cultivation of any amount carries penalties of 5-15 years imprisonment and fines of 500,000-1,500,000 baht. Section 22 prohibits sales to minors under 20 years of age, with penalties of 3-10 years imprisonment. This provision applies even to licensed medical dispensaries. Section 28 establishes physician licensing requirements. Doctors must complete a 40-hour certification program administered by the Medical Council of Thailand to prescribe cannabis. As of June 2026, only 89 physicians have completed this training. Section 31 restricts advertising and marketing of cannabis products, prohibiting any promotion that could be construed as encouraging recreational use. Violations carry penalties of 1-3 years imprisonment and fines of 100,000-300,000 baht. The Act includes no grandfather provisions or compensation mechanisms for businesses or farmers who invested during the 2022-2025 period. Legal challenges arguing that the lack of transition protections violates constitutional property rights were rejected by the Constitutional Court in March 2026. Enforcement has been aggressive. The Royal Thai Police reported 8,947 arrests for cannabis-related offenses in the first quarter of 2026, compared to 1,203 arrests in the first quarter of 2022 (pre-decriminalization). Most arrests involve possession of small amounts (under 25 grams) for personal use. Prosecutors have pursued imprisonment in approximately 30% of cases, with the remainder receiving fines and probation. The regulatory framework for medical cannabis remains underdeveloped. The Ministry of Public Health has issued regulations specifying approved conditions, but has not published clinical guidelines for physicians. Dosing recommendations, drug interaction warnings, and monitoring protocols are left to individual physician discretion. The Thai FDA has approved only 23 cannabis products, all in oil or capsule form—no dried flower or vaporizable products are permitted even for medical use. Thailand remains a signatory to the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. The government has argued that the 2024 Cannabis Control Act brings Thailand back into compliance with these treaties, though some international law scholars contend that the 2022-2025 decriminalization period did not violate treaty obligations because the conventions permit medical and scientific use.

Regional and International Implications

Thailand's reversal has frozen cannabis reform momentum across Southeast Asia and reinforced prohibitionist arguments in regional forums, potentially delaying liberalization efforts in Malaysia, Philippines, and Vietnam by 5-10 years. The Association of Southeast Asian Nations (ASEAN) maintains a strong prohibitionist stance through the ASEAN Drug-Free 2025 initiative (extended to 2030). Thailand's brief liberalization created tension within ASEAN, with Singapore and Brunei expressing concern about cross-border trafficking and drug tourism. The reversal has been cited by prohibitionist governments as validation of their policies. In Malaysia, the Health Ministry cited Thailand's "failed experiment" when rejecting a medical cannabis proposal in February 2026. Malaysian Health Minister Dr. Zaliha Mustafa stated that "Thailand's experience shows that decriminalization without strict controls leads to youth usage and public health harms"—a position that patient advocates argue mischaracterizes Thailand's regulatory failures as inherent to liberalization. Singapore has used Thailand's reversal in domestic policy debates. The Ministry of Home Affairs referenced Thai emergency room data and youth usage statistics in March 2026 parliamentary testimony defending Singapore's mandatory death penalty for cannabis trafficking over 500 grams. Singapore maintains one of the world's strictest cannabis prohibitions, with possession of any amount punishable by up to 10 years imprisonment. The Philippines, which had been considering medical cannabis legislation, saw reform momentum collapse following Thailand's reversal. A medical cannabis bill that had advanced through committee in the Philippine House of Representatives in 2024 was shelved indefinitely in January 2026. Philippine Drug Enforcement Agency officials cited Thailand as evidence that "Asian societies are not ready for cannabis liberalization." Vietnam's Ministry of Health, which had commissioned a study on medical cannabis in 2023, cancelled the project in early 2026 and reaffirmed Vietnam's commitment to cannabis prohibition. Vietnamese state media extensively covered Thailand's reversal as a cautionary tale. The international cannabis industry has reassessed Asian market opportunities. Investment in Asian cannabis ventures declined 89% in 2025 compared to 2023 according to data from Viridian Capital Advisors. Industry executives now view Asian markets as high-risk, requiring decades-long timelines for liberalization and stable regulatory frameworks.

Market and Business Implications

The Thailand reversal destroyed an estimated $2.6 billion in market value, eliminated over 30,000 jobs, and created a case study in regulatory risk that has fundamentally altered how cannabis companies evaluate emerging market opportunities. The dispensary sector collapsed almost entirely. Of the 6,127 registered dispensaries operating in December 2025, only 127 obtained licenses to operate as medical-only pharmacies under the new system. The remaining 6,000 closed permanently, with owners unable to recoup investments in leases, renovations, inventory, and equipment. Average dispensary closure losses are estimated at 4-8 million baht per location, totaling 24-48 billion baht across the sector. Cultivation operations faced similar devastation. The 125,000 registered cultivators who grew cannabis during 2022-2025 were left with no legal market. Approximately 180 metric tons of dried flower inventory became unsellable overnight. Wholesale prices for cannabis flower, which had stabilized at 80-120 baht per gram in late 2025, collapsed to zero for legal inventory. Black market prices increased sharply—from 200-300 baht per gram in December 2025 to 600-900 baht per gram by March 2026—as supply constricted and risk premiums increased. The agricultural impact has been concentrated in northern provinces. In Chiang Mai province alone, an estimated 12,000 farmers had transitioned to cannabis cultivation. These farmers had invested in greenhouses, irrigation systems, and drying facilities—capital expenditures averaging 800,000-1.5 million baht per farm. With no legal market and no compensation program, many farmers face bankruptcy and loss of family land used as loan collateral. International investors absorbed massive losses. Publicly-traded companies reported the following write-offs in 2025-2026 financial statements:

• Canopy Growth Corporation: $180 million write-off of Thai joint venture
• Tilray Brands: $95 million impairment of Thai distribution investment
• Aurora Cannabis: $67 million write-off of greenhouse partnership
• Supreme Cannabis (acquired by Canopy): $43 million loss on Thai cultivation facility

These losses contributed to broader financial distress in the international cannabis sector, with several companies citing Thailand as a factor in restructuring decisions and workforce reductions. The Thai Cannabis Corporation, the most prominent domestic publicly-traded cannabis company, saw its market capitalization decline from 62 billion baht at its March 2023 peak to 3.7 billion baht in June 2026—a 94% loss. The company has pivoted to CBD wellness products (which remain legal under 0.2% THC limits) and international markets, but revenues declined 87% year-over-year in Q1 2026. Employment losses have been severe. The Thai Cannabis Trade Association estimates that 32,000 direct jobs were eliminated in the dispensary, cultivation, and processing sectors between January-June 2026. Indirect job losses in tourism, hospitality, and ancillary services add an estimated 15,000-20,000 additional positions. The government has offered no retraining programs or unemployment assistance specific to cannabis sector workers. The reversal has created a robust black market. Law enforcement officials estimate that 40-60% of former legal dispensaries continue operating underground, along with traditional illicit suppliers. The black market is now larger than it was pre-2022, with more sophisticated distribution networks and higher-quality products due to knowledge and genetics that diffused during the legal period. This outcome—a larger, more sophisticated illicit market—represents the opposite of the government's stated policy goals. For the broader cannabis industry, Thailand has become a case study in political and regulatory risk. Investment committees at cannabis companies now routinely reference Thailand when evaluating emerging market opportunities. The consensus view is that ministerial or executive-branch liberalization without durable legislative frameworks creates unacceptable risk, and that emerging markets require 5-10 year track records of stable policy before significant capital deployment.

What Experts Say

Policy analysts, public health researchers, and industry observers largely agree that Thailand's reversal stemmed from implementing decriminalization without comprehensive regulation, though they differ on whether the underlying liberalization policy was sound. Dr. Suranart Kanjanavanit, a public health professor at Chulalongkorn University who advised the Ministry of Public Health, has argued that the 2022 decriminalization was "premature and poorly designed." According to Dr. Suranart, the policy failed to establish age restrictions, quality standards, or potency limits, leading to predictable public health harms. He has stated that a properly regulated medical cannabis program could serve Thai patients, but that recreational legalization is inappropriate for Thai society. Dr. Suranart's research on emergency room admissions has been widely cited by recriminalization advocates, though critics note his studies did not control for increased reporting due to reduced stigma. Martin Jelsma, director of the Drugs & Democracy program at the Transnational Institute, has characterized Thailand's reversal as a "tragic policy failure" that will harm patients and enrich criminal networks. Jelsma has argued that the problems stemmed from regulatory gaps rather than inherent flaws in liberalization, and that the government's response—full recriminalization—was disproportionate and counterproductive. He has noted that jurisdictions including Canada, Uruguay, and several U.S. states experienced similar implementation challenges but addressed them through regulatory refinement rather than reversal. Tanadej Vechakij, a Bangkok-based cannabis entrepreneur who operated three dispensaries during 2022-2025, has described the reversal as "economic destruction driven by political opportunism." According to Tanadej, the government encouraged investment through the 2022 decriminalization, then reversed course when politically convenient without regard for business owners and farmers who acted in good faith. He has called for a compensation program modeled on eminent domain principles, though legal experts consider such claims unlikely to succeed given the Constitutional Court's rulings. Dr. Niyada Kiatying-Angsulee, director of the Research Institute for Health Sciences at Chiang Mai University, has focused on the agricultural impact. Her research team documented that cannabis cultivation provided income averaging 180,000-240,000 baht per hectare compared to 40,000-60,000 baht for traditional crops like rice and corn. Dr. Niyada has argued that the reversal has pushed farmers back into poverty and potentially back toward opium cultivation, undermining decades of crop substitution efforts. She has advocated for a hemp-focused policy that would allow low-THC cultivation for fiber and CBD extraction. International observers have viewed Thailand's reversal through the lens of emerging market risk. Steve Hawkins, executive director of the U.S. Marijuana Policy Project, stated in a March 2026 interview that Thailand demonstrates why "ministerial decrees and executive actions are insufficient foundations for cannabis policy reform." He has argued that durable liberalization requires legislative frameworks with broad political support and transition provisions that protect legitimate businesses. The Thai Medical Council, which represents physicians, has maintained that cannabis has legitimate medical applications but requires the same regulatory rigor as other controlled medications. The Council supported recriminalization while advocating for a functional medical access system. However, the Council has criticized the Ministry of Public Health for creating excessive barriers in the physician certification program, arguing that the 40-hour training requirement is disproportionate compared to requirements for prescribing opioids or benzodiazepines. Patient advocates have been uniformly critical of the reversal. Prasitchai Nunual, founder of the Thai Cannabis Patient Network, has documented cases of patients forced back onto opioid pain medications or experiencing seizure recurrence after losing cannabis access. According to Prasitchai, the new medical system serves fewer than 2% of patients who benefited from cannabis during 2022-2025, creating a humanitarian crisis that the government refuses to acknowledge.

What's Next

Thailand's cannabis policy is unlikely to liberalize again in the near term, with the earliest realistic opportunity for reform coming after the next general election scheduled for 2027, though even that timeline is optimistic given current political dynamics. The immediate future involves continued enforcement of the Cannabis Control Act. The Royal Thai Police has indicated that cannabis enforcement is a priority for 2026-2027, with resources redirected from methamphetamine interdiction. Arrest rates are projected to reach 35,000-40,000 annually, primarily for possession offenses. Prisons, already operating at 130% capacity according to the Department of Corrections, face further overcrowding. The medical cannabis system will likely expand slowly. The Ministry of Public Health has stated a goal of certifying 500 physicians by the end of 2026 and 2,000 by 2028. If achieved, this would improve access but still serve only a fraction of potential medical patients. The Thai FDA has indicated it will approve additional cannabis products, potentially including dried flower for vaporization, though no timeline has been announced. Legal challenges will continue. The Thai Cannabis Trade Association has filed a new constitutional challenge arguing that the lack of compensation for businesses violates property rights protections in the 2017 Constitution. Legal experts give this challenge minimal chance of success given the Constitutional Court's